Skip to content

Arvinas ARVN Deferred revenue, net of current portion

Deferred revenue, net of current portion at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
Arcus Biosciences logo
Arcus BiosciencesRCUS

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Operating income-$63.8M-189%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
CapEx$1.3M+225%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$518.11M-4.6%
Enterprise value$439.41M-7.1%
P/S5.8×+4.5×

Profitability

See full
Operating margin-283.8%-310pp
Net margin-247.5%-260pp
FCF margin-287.4%

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0.0×
Current ratio5.4×+0.9×

Where this comes from

Reported directly by Arvinas in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Arvinas’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arvinas's deferred revenue, net of current portion.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arvinas's deferred revenue, net of current portion?
Arvinas (ARVN) reported deferred revenue, net of current portion of $138.2M in Q1 2026.
How has Arvinas's deferred revenue, net of current portion changed year-over-year?
Arvinas's deferred revenue, net of current portion increased by 16.7% year-over-year, from $118.4M to $138.2M.
What is the long-term trend for Arvinas's deferred revenue, net of current portion?
Over 5 years (2020 to 2025), Arvinas's deferred revenue, net of current portion has grown at a 42.4% compound annual growth rate (CAGR), from $22.9M to $134.3M.